Header Logo

Connection

JOHN VIERLING to Female

Back to Details
This is a "connection" page, showing publications JOHN VIERLING has written about Female.
JOHN VIERLING
Connection Strength
0.486
Female
  1. Primary biliary cholangitis. Lancet. 2024 09 14; 404(10457):1053-1066.
    View in: PubMed
    Score: 0.034
  2. Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. Pathology. 2022 Oct; 54(6):686-693.
    View in: PubMed
    Score: 0.029
  3. Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675.
    View in: PubMed
    Score: 0.021
  4. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug; 61(2):200-9.
    View in: PubMed
    Score: 0.017
  5. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014 Apr; 60(4):748-56.
    View in: PubMed
    Score: 0.016
  6. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014 May; 34(5):707-19.
    View in: PubMed
    Score: 0.016
  7. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012 Aug; 56(2):464-73.
    View in: PubMed
    Score: 0.015
  8. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health. 2010 Apr 01; 100 Suppl 1:S118-24.
    View in: PubMed
    Score: 0.012
  9. Comparison of the applicability of two prognostic scoring systems in patients with fulminant hepatic failure. Korean J Intern Med. 2007 Jun; 22(2):93-100.
    View in: PubMed
    Score: 0.010
  10. Statin Use Is Associated With Protection Against Acute Cholangitis in Patients With Primary Sclerosing Cholangitis: A Multicenter Retrospective Cohort Study. Clin Transl Gastroenterol. 2025 Apr 01; 16(4):e00816.
    View in: PubMed
    Score: 0.009
  11. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Oct; 167(5):1008-1018.e5.
    View in: PubMed
    Score: 0.008
  12. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis. 2004 Feb; 8(1):177-94.
    View in: PubMed
    Score: 0.008
  13. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol. 2023 12; 8(12):1118-1128.
    View in: PubMed
    Score: 0.008
  14. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS One. 2021; 16(11):e0260320.
    View in: PubMed
    Score: 0.007
  15. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
    View in: PubMed
    Score: 0.007
  16. Presentation and Outcomes of Autoimmune Hepatitis Type 1 and Type 2 in Children: A Single-center Study. J Pediatr Gastroenterol Nutr. 2021 01 01; 72(1):101-107.
    View in: PubMed
    Score: 0.007
  17. Case studies of the hepatitis B patient: a panel discussion. Semin Liver Dis. 2000; 20 Suppl 1:29-35.
    View in: PubMed
    Score: 0.006
  18. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun. 2019 12; 105:102328.
    View in: PubMed
    Score: 0.006
  19. Immortalized intrahepatic mouse biliary epithelial cells: immunologic characterization and immunogenicity. Hepatology. 1999 Aug; 30(2):358-71.
    View in: PubMed
    Score: 0.006
  20. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019 07; 101:26-34.
    View in: PubMed
    Score: 0.006
  21. No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg. 2019 01; 269(1):20-27.
    View in: PubMed
    Score: 0.006
  22. Predicting Liver Allograft Discard: The Discard Risk Index. Transplantation. 2018 09; 102(9):1520-1529.
    View in: PubMed
    Score: 0.006
  23. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018 06; 113(6):863-871.
    View in: PubMed
    Score: 0.005
  24. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 01 25; 378(4):354-369.
    View in: PubMed
    Score: 0.005
  25. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May; 53(5):679-688.
    View in: PubMed
    Score: 0.005
  26. Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018 05; 195:25-47.
    View in: PubMed
    Score: 0.005
  27. Liver transplant length of stay (LOS) index: A novel predictive score for hospital length of stay following liver transplantation. Clin Transplant. 2017 Dec; 31(12).
    View in: PubMed
    Score: 0.005
  28. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clin Gastroenterol Hepatol. 2018 02; 16(2):278-287.e7.
    View in: PubMed
    Score: 0.005
  29. Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 10; 2(10):716-726.
    View in: PubMed
    Score: 0.005
  30. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 11; 2(11):814-823.
    View in: PubMed
    Score: 0.005
  31. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
    View in: PubMed
    Score: 0.005
  32. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845.
    View in: PubMed
    Score: 0.005
  33. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017 01; 152(1):164-175.e4.
    View in: PubMed
    Score: 0.005
  34. Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int. 2016 Nov; 10(6):909-915.
    View in: PubMed
    Score: 0.005
  35. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5):1493-505.
    View in: PubMed
    Score: 0.005
  36. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology. 1995 Nov; 22(5):1379-86.
    View in: PubMed
    Score: 0.005
  37. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2016 Feb; 23(2):80-8.
    View in: PubMed
    Score: 0.005
  38. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na?ve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct; 42(7):829-44.
    View in: PubMed
    Score: 0.005
  39. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
    View in: PubMed
    Score: 0.004
  40. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul; 63(1):30-7.
    View in: PubMed
    Score: 0.004
  41. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med. 1994 Nov 15; 121(10):729-35.
    View in: PubMed
    Score: 0.004
  42. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015 Mar 21; 385(9973):1087-97.
    View in: PubMed
    Score: 0.004
  43. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
    View in: PubMed
    Score: 0.004
  44. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56.
    View in: PubMed
    Score: 0.004
  45. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46.
    View in: PubMed
    Score: 0.004
  46. Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation. Dig Dis Sci. 1994 Jun; 39(6):1351-8.
    View in: PubMed
    Score: 0.004
  47. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014 Jun; 20(6):724-7.
    View in: PubMed
    Score: 0.004
  48. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6.
    View in: PubMed
    Score: 0.004
  49. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014 Mar; 59(3):1073-83.
    View in: PubMed
    Score: 0.004
  50. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013 Nov 09; 13:534.
    View in: PubMed
    Score: 0.004
  51. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37.
    View in: PubMed
    Score: 0.004
  52. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23.
    View in: PubMed
    Score: 0.004
  53. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15; 381(9883):2100-7.
    View in: PubMed
    Score: 0.004
  54. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013 Mar; 58(3):479-87.
    View in: PubMed
    Score: 0.004
  55. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):81-87.e4; quiz e5.
    View in: PubMed
    Score: 0.004
  56. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012 Jul; 8(4):e32-9.
    View in: PubMed
    Score: 0.004
  57. Suppressor function of liver mononuclear cells isolated during murine chronic graft-vs-host disease. II. Role of prostaglandins and interferon-gamma. Cell Immunol. 1992 Mar; 140(1):54-66.
    View in: PubMed
    Score: 0.004
  58. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012 Feb; 55(2):512-21.
    View in: PubMed
    Score: 0.004
  59. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31; 364(13):1207-17.
    View in: PubMed
    Score: 0.003
  60. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep; 52(3):822-32.
    View in: PubMed
    Score: 0.003
  61. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28; 376(9742):705-16.
    View in: PubMed
    Score: 0.003
  62. Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease. J Immunol. 1989 Jul 15; 143(2):476-83.
    View in: PubMed
    Score: 0.003
  63. Transmission of hepatitis B virus by artificial insemination. JAMA. 1987 Feb 27; 257(8):1079-81.
    View in: PubMed
    Score: 0.003
  64. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant. 2006 Sep; 6(9):2177-82.
    View in: PubMed
    Score: 0.002
  65. Management of patients with cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol. 2006 Feb; 40(2):156-61.
    View in: PubMed
    Score: 0.002
  66. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006 Feb; 21(2):381-3.
    View in: PubMed
    Score: 0.002
  67. Electron microscopy of rejected human liver allografts. Hepatology. 1985 Nov-Dec; 5(6):1083-7.
    View in: PubMed
    Score: 0.002
  68. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005 Nov; 42(5):1194-202.
    View in: PubMed
    Score: 0.002
  69. Morbidity in live liver donors: standards-based adverse event reporting further refined. Arch Surg. 2005 Sep; 140(9):888-95; discussion 895-6.
    View in: PubMed
    Score: 0.002
  70. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol. 2005 Jan; 39(1):75-7.
    View in: PubMed
    Score: 0.002
  71. Ultrastructural immunocytochemical localization of the asialoglycoprotein receptor in rat hepatocytes. Gastroenterology. 1984 Oct; 87(4):763-9.
    View in: PubMed
    Score: 0.002
  72. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut. 2004 Sep; 53(9):1389-90.
    View in: PubMed
    Score: 0.002
  73. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004 Sep; 28(9):1204-11.
    View in: PubMed
    Score: 0.002
  74. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther. 2004 May 01; 19(9):1033-9.
    View in: PubMed
    Score: 0.002
  75. Cellular distribution of the asialoglycoprotein receptor in rat liver. Implications for hepatic accumulation of desialylated lymphocytes. Gastroenterology. 1984 Jan; 86(1):142-9.
    View in: PubMed
    Score: 0.002
  76. Epidemiology and clinical course of liver diseases: identification of candidates for hepatic transplantation. Hepatology. 1984 Jan-Feb; 4(1 Suppl):84S-94S.
    View in: PubMed
    Score: 0.002
  77. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003 Aug; 125(2):298-303.
    View in: PubMed
    Score: 0.002
  78. Relationship of pretransplant hepatobiliary disease to bile duct damage occurring in the liver allograft. Hepatology. 1983 Jan-Feb; 3(1):84-9.
    View in: PubMed
    Score: 0.002
  79. Hepatic injury by prescription medication. Med Sect Proc. 1983; 79-86.
    View in: PubMed
    Score: 0.002
  80. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transpl. 2002 Oct; 8(10):925-31.
    View in: PubMed
    Score: 0.002
  81. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999 Jan; 94(1):241-8.
    View in: PubMed
    Score: 0.001
  82. Survey results of transplant patients' attitudes on xenografting. Psychosomatics. 1998 Jul-Aug; 39(4):379-83.
    View in: PubMed
    Score: 0.001
  83. Incorporation of radiocopper into ceruloplasmin in normal subjects and in patients with primary biliary cirrhosis and Wilson's disease. Gastroenterology. 1978 Apr; 74(4):652-60.
    View in: PubMed
    Score: 0.001
  84. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998 Jan; 27(1):213-22.
    View in: PubMed
    Score: 0.001
  85. In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. J Clin Invest. 1977 Nov; 60(5):1116-28.
    View in: PubMed
    Score: 0.001
  86. Treatment of acetaminophen-induced fulminant hepatic failure with a bioartificial liver. Transplant Proc. 1997 Feb-Mar; 29(1-2):487-8.
    View in: PubMed
    Score: 0.001
  87. Hepatitis C virus is not recoverable from liver tissue in cryptogenic cirrhosis: failure to identify hepatitis C virus-RNA using reverse transcription-mediated polymerase chain reaction. Hum Pathol. 1996 Nov; 27(11):1161-5.
    View in: PubMed
    Score: 0.001
  88. Transjugular intrahepatic portosystemic shunt: efficacy for the treatment of portal hypertension and impact on liver transplantation. Am Surg. 1996 Oct; 62(10):835-9.
    View in: PubMed
    Score: 0.001
  89. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. Transplant Proc. 1996 Apr; 28(2):1011-3.
    View in: PubMed
    Score: 0.001
  90. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr. 1995 Nov; 127(5):815-8.
    View in: PubMed
    Score: 0.001
  91. Portal vein patency in candidates for liver transplantation: MR angiographic analysis. Radiology. 1995 Oct; 197(1):147-52.
    View in: PubMed
    Score: 0.001
  92. Effect of splenectomy of hepatic bilirubin clearance in patients with hereditary spherocytosis. Implications for the diagnosis of Gilbert's syndrome. J Lab Clin Med. 1981 Jul; 98(1):37-45.
    View in: PubMed
    Score: 0.000
  93. Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest. 1978 Nov; 62(5):1069-77.
    View in: PubMed
    Score: 0.000
  94. Abnormal hepatic transport of indocyanine green in Gilbert's syndrome. Gastroenterology. 1976 Mar; 70(3):385-91.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.